Viewing data from:

DOXEPIN HYDROCHLORIDE

ANDA

DOXEPIN HYDROCHLORIDE | A214823 | MSN LABORATORIES PRIVATE LTD

2 strengths0 unique patents0 unique exclusivities

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Currax Pharmaceuticals LLC v. MSN Laboratories Private Limited et al. 1:2020cv01064 6 patentsANDA 214823doxepin hydrochloride	D. Del.	2020-08-13	Terminated 2022-11-16	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$1.59

per ea

Lowest NADAC/Unit

$1.36

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
72205005330DOXEPIN HCL 6 MG TABLET	$1.59	EA	Generic	—	2026-06-17
72205005230DOXEPIN HCL 3 MG TABLET	$1.36	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (2 FSS)

Lowest Price

$22.44

Highest Price

$26.62

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
51407-0811-30DOXEPIN 3MG TAB	$22.44	FSS	Golden State Medical Supply, Inc.	06/14/2028
51407-0812-30DOXEPIN 6MG TAB	$26.62	FSS	Golden State Medical Supply, Inc.	06/14/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain4 active DMFs2 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

OLON SPADOXEPIN HYDROCHLORIDE

DMF 50251983

MSN LIFE SCIENCES PRIVATE LTDDOXEPIN HYDROCHLORIDE USP

DMF 335592019

R L FINE CHEM PVT LTDDOXEPIN HYDROCHLORIDE

DMF 344382020

RAKS PHARMA PVT LTDDOXEPIN HYDROCHLORIDE USP

DMF 350172020

BOEHRINGER MANNHEIM GMBHInactiveDOXEPIN

DMF 24101975

GANES CHEMICALS INC PENNSVILLE DIVInactiveDOXEPIN HYDROCHLORIDE

DMF 68561987

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 3MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Apr 3, 2023

No patent or exclusivity listings for this strength.

#002 — EQ 6MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Apr 3, 2023